Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients.
OBJECTIVE
To evaluate the long-term results of aggressive treatment of HCC recurrence.


METHODS
Two hundred and nine consecutive patients underwent hepatic resection for HCC in our hospital. Tumour recurrence was diagnosed in 97 (51%) of the 190 patients with curative resection. Sixteen underwent hepatic resection: two right hepatectomies, one three-segmentectomy, one left hepatectomy, five two-segmentectomies, six segmental resections and one subsegmentectomy. Two patients with metastasis in the spine were submitted to a vertebral body resection. Twenty-five patients were treated with percutaneous ethanol injection or intra-arterial chemoembolization. Fifty-four patients with a poor performance status and liver function or multiple extra hepatic recurrences did not receive any treatment.


RESULTS
There were no operative deaths. The postoperative mortality rate was 5.5% (one patient). The cumulative overall survival after the second resection was respectively 89%, 46% and 31% at 1, 3 and 5 years. There was a significant difference in survival between patients treated with repeat resection and those submitted to a non-surgical or conservative treatment (p<0.0001). There were no differences in operative deaths, postoperative mortality and morbidity between the first and second hepatic resection.


CONCLUSIONS
Aggressive management with combined resection or loco regional therapy for intrahepatic recurrence and resection of isolated extra-hepatic recurrence may offer long-term survival in selected patients. Second liver resection for recurrence of HCC can be safely performed.
Tralhão
J G
JG
Service de Chirurgie Générale, Hôpital Antoine-Béclère, Faculté de Médecine Paris-Sud, France. jglrt@hotmail.com
Dagher
I
I
Lino
T
T
Roudié
J
J
Franco
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000601:surgery*; D016461:Chemoembolization, Therapeutic; D018572:Disease-Free Survival; D000431:Ethanol / Q000627:therapeutic use; D005260:Female; D006498:Hepatectomy / Q000145:classification / Q000379:methods; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000601:surgery*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery* / Q000628:therapy; D012086:Reoperation; D013125:Spinal Neoplasms / Q000556:secondary / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000431:Ethanol